Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999839 | Urologic Oncology: Seminars and Original Investigations | 2012 | 10 Pages |
Abstract
Chemotherapy with docetaxel remains the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). To date there is no recommended second-line therapy in case of progression after docetaxel treatment. Knowledge of the molecular and cellular changes that occur during the transition of hormone-native to CRPC is increasing rapidly opening new therapy strategies in CRPC patients. This article will focus on recent available therapy options for patients with progressive CRPC after first-line treatment with docetaxel and highlights promising novel substances that are currently under investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Christian Arsov, Christian Winter, Robert Rabenalt, Peter Albers,